Merck & Company News - July 15, 2026
Merck to Unveil Phase 3 Data on Once-Weekly HIV Regimen at AIDS 2026
Merck will present new data from its HIV treatment and prevention pipeline. The company will present this data at the 26th International AIDS Conference (AIDS...
Merck Keytruda Beats Chemotherapy, Offering New Option for Endometrial Cancer
Merck’s Phase 3 KEYNOTE-C93 trial met its primary endpoint for the treatment of endometrial cancer. Keytruda monotherapy significantly improved...
Merck Secures EU Approval for Erbitux, Driving Wall Street Price Hikes
The European Commission approved Merck’s Erbitux on July 14, 2026. This regulatory green light covers Erbitux in combination with encorafenib and FOLFOX for...